Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Journal of Hepatology|April 19, 2006
Macrophage activating syndrome is associated with lobular hepatitis and severe bile duct injury with cholestasisFlorian Bihl, Urban Emmenegger, Jürg Reichen, et al.
Frontiers in Oncology|December 4, 2025
Case Report: Rare meets rare-miliary prostate cancer brain metastasisJaspreet K Gill, Jay Detsky, Eyal Golan, et al.
Investigational New Drugs|June 4, 2013
Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapyAnnabelle Chow, Amy Wong, Giulio Francia, et al.
Breast (Edinburgh, Scotland)|October 4, 2005
Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapyRaquel Munoz, Yuval Shaked, Francesco Bertolini, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 11, 2019
Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisoneSamuel Dubinsky, Alia Thawer, Anne G McLeod, et al.
Frontiers in Oncology|May 24, 2021
Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate CancerJuan Briones, Maira Khan, Amanjot K Sidhu, et al.
Neoplasia (New York, N.Y.)|January 20, 2011
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamideUrban Emmenegger, Giulio Francia, Annabelle Chow, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 21, 2021
A cost-utility analysis of apalutamide for metastatic castrationsensitive prostate cancerAmbica Parmar, Narhari Timilshina, Urban Emmenegger, et al.
Neoplasia (New York, N.Y.)|November 16, 2010
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapyTerence C Tang, Shan Man, Ping Xu, et al.
Blood|July 7, 2005
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activityYuval Shaked, Urban Emmenegger, Shan Man, et al.
Pageof 10